You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

TEKTURNA HCT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Tekturna Hct, and what generic alternatives are available?

Tekturna Hct is a drug marketed by Noden Pharma and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-five countries.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this compound. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

DrugPatentWatch® Generic Entry Outlook for Tekturna Hct

Tekturna Hct was eligible for patent challenges on March 5, 2011.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 13, 2028. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for TEKTURNA HCT
Drug patent expirations by year for TEKTURNA HCT
Drug Prices for TEKTURNA HCT

See drug prices for TEKTURNA HCT

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for TEKTURNA HCT
Generic Entry Date for TEKTURNA HCT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TEKTURNA HCT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Wayne State UniversityPhase 4
University of Alabama at BirminghamPhase 4
Mayo ClinicN/A

See all TEKTURNA HCT clinical trials

Paragraph IV (Patent) Challenges for TEKTURNA HCT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
TEKTURNA HCT Tablets aliskiren hemifumarate; hydrochlorothiazide 150 mg/12.5 mg 150 mg/25 mg 300 mg/12.5 mg 300 mg/25 mg 022107 1 2014-03-07

US Patents and Regulatory Information for TEKTURNA HCT

TEKTURNA HCT is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of TEKTURNA HCT is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting TEKTURNA HCT

Galenical formulations of organic compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-001 Jan 18, 2008 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-004 Jan 18, 2008 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-002 Jan 18, 2008 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TEKTURNA HCT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-004 Jan 18, 2008 ⤷  Try a Trial ⤷  Try a Trial
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-001 Jan 18, 2008 ⤷  Try a Trial ⤷  Try a Trial
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-003 Jan 18, 2008 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TEKTURNA HCT

When does loss-of-exclusivity occur for TEKTURNA HCT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1565
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 07263261
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0713338
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 54872
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 07001837
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1472566
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 088986
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 34968
Estimated Expiration: ⤷  Try a Trial

Patent: 11439
Estimated Expiration: ⤷  Try a Trial

Patent: 91878
Estimated Expiration: ⤷  Try a Trial

Guatemala

Patent: 0800297
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 5425
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 62556
Estimated Expiration: ⤷  Try a Trial

Patent: 09541239
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 6779
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 08016533
Estimated Expiration: ⤷  Try a Trial

Morocco

Patent: 527
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 2937
Estimated Expiration: ⤷  Try a Trial

Norway

Patent: 090262
Estimated Expiration: ⤷  Try a Trial

Peru

Patent: 080373
Estimated Expiration: ⤷  Try a Trial

Patent: 120990
Estimated Expiration: ⤷  Try a Trial

Russian Federation

Patent: 91058
Estimated Expiration: ⤷  Try a Trial

Patent: 09101971
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0809773
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1442272
Estimated Expiration: ⤷  Try a Trial

Patent: 090021353
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 04979
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 57137
Estimated Expiration: ⤷  Try a Trial

Patent: 0808358
Estimated Expiration: ⤷  Try a Trial

Tunisia

Patent: 08528
Estimated Expiration: ⤷  Try a Trial

United Kingdom

Patent: 12540
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TEKTURNA HCT around the world.

Country Patent Number Title Estimated Expiration
Norway 310410 ⤷  Try a Trial
Japan 5362556 ⤷  Try a Trial
Portugal 1915993 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for TEKTURNA HCT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1915993 2013C/068 Belgium ⤷  Try a Trial PRODUCT NAME: COMBINAISON COMPRENANT L'ALISKIREN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET L'AMLOPINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/11/686/001 20110415
0678503 C300296 Netherlands ⤷  Try a Trial PRODUCT NAME: ALISKIREN OF EEN; REGISTRATION NO/DATE: EU/1/07/405/001-020 20070822
2305232 C201930070 Spain ⤷  Try a Trial PRODUCT NAME: ALISKIREN HEMIFUMARATO + HIDROCLOROTIAZIDA; NATIONAL AUTHORISATION NUMBER: EU/1/08/491/001-080; DATE OF AUTHORISATION: 20090116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/08/491/001-080; DATE OF FIRST AUTHORISATION IN EEA: 20090116
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.